Spots Global Cancer Trial Database for Blood Detection of EGFR Mutation For Iressa Treatment

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Blood Detection of EGFR Mutation For Iressa Treatment

Official Title: Blood Detection of EGFR Mutation For Iressa Treatment

Study ID: NCT02282267

Conditions

Lung Adenocarcinoma

Interventions

Gefitinib

Study Description

Brief Summary: This study was proposed to validate the efficacy of gefitinib as first-line therapy in advanced lung adenocarcinoma with EGFR mutation determined by plasma cf-DNA.

Detailed Description: Patients without enough tissue for EGFR mutation detection can also have opportunity to use EGFR-TKI as first line therapy. Meanwhile, this study was also proposed to explore the best intervention time of anti-resistant drugs (such as AZD 9291, a T790M inhibitor) through the quantitative and dynamic analysis of EGFR sensitive and resistant mutation in plasma cf-DNA during EGFR-TKI treatment process.